2022
DOI: 10.3389/fimmu.2022.920021
|View full text |Cite
|
Sign up to set email alerts
|

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades

Abstract: Developing biomarkers for accurately predicting the efficacy of immune checkpoint inhibitor (ICI) therapies is conducive to avoiding unwanted side effects and economic burden. At the moment, the quantification of programmed cell death ligand 1 (PD-L1) in tumor tissues is clinically used as one of the combined diagnostic assays of response to anti-PD-1/PD-L1 therapy. However, the current assays for evaluating PD-L1 remain imperfect. Recent studies are promoting the methodologies of PD-L1 evaluation from rough t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
33
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(35 citation statements)
references
References 147 publications
2
33
0
Order By: Relevance
“…In particular, we would like to propose that combination therapies with Pxl, and possibly its derivatives, and ICIs, especially anti PD-L1/PD targets, should be approached first by a low dosage, rather than near to maximum tolerated, Pxl regimen in order to render “hot” the tumor microenvironment and to “prime” cancer cells for a sequential, rather than concurrent, treatment with ICIs (see Figure 5 ) ( 14 , 15 , 27 , 35 , 39 ). In addition, our data further support the evaluation of cGAS levels as a biomarker, that could be more technically reliable than evaluation of PD-L1 itself, to predict beneficial effects of an ICI adjuvant treatment when Pxl and derivatives are used in neodjuvant setting ( 40 ).…”
Section: Discussionsupporting
confidence: 63%
“…In particular, we would like to propose that combination therapies with Pxl, and possibly its derivatives, and ICIs, especially anti PD-L1/PD targets, should be approached first by a low dosage, rather than near to maximum tolerated, Pxl regimen in order to render “hot” the tumor microenvironment and to “prime” cancer cells for a sequential, rather than concurrent, treatment with ICIs (see Figure 5 ) ( 14 , 15 , 27 , 35 , 39 ). In addition, our data further support the evaluation of cGAS levels as a biomarker, that could be more technically reliable than evaluation of PD-L1 itself, to predict beneficial effects of an ICI adjuvant treatment when Pxl and derivatives are used in neodjuvant setting ( 40 ).…”
Section: Discussionsupporting
confidence: 63%
“…In clinical trials, PD-L1 tumor expression is considered a poor predictor of objective response to checkpoint inhibition, where patients benefit from the treatment independently of PD-L1 expression levels detected in tumor samples [ 12 , 23 , 32 ]. This can be explained by its dynamic and heterogeneous expression [ 33 , 34 ], which varies upon disease progression [ 35 ] and different treatment protocols, including ICB [ 36 ]. Moreover, there are several reasons that could explain the heterogeneity in levels of PD-L1 expression as a predictable biomarker of response: differences in tissue samples, PD-L1 expression cut-off, the use of TPS or CPS, as well as the detection technique used.…”
Section: Discussionmentioning
confidence: 99%
“…The immunosuppressive costimulatory signal receptor PD-1 is expressed on activated T and B cells [ 302 , 303 ]. PD-L1 is strongly expressed by various solid tumors, B tumor cells (including DLBCL and MM cells), and BM stromal cells [ 303 , 304 ].…”
Section: Clinical Trials Of Novel Anti-taa Inhibitors In the Treatmen...mentioning
confidence: 99%
“…The immunosuppressive costimulatory signal receptor PD-1 is expressed on activated T and B cells [ 302 , 303 ]. PD-L1 is strongly expressed by various solid tumors, B tumor cells (including DLBCL and MM cells), and BM stromal cells [ 303 , 304 ]. As the tumor develops, both PD-1 and PD-L1 cause tumor immune escape–mainly by inhibiting the activity of tumor-infiltrating lymphocytes [ 303 , 304 ].…”
Section: Clinical Trials Of Novel Anti-taa Inhibitors In the Treatmen...mentioning
confidence: 99%
See 1 more Smart Citation